WallStreetZenWallStreetZen

NASDAQ: XLO
Xilio Therapeutics Inc Stock Ownership - Who owns Xilio Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Xilio Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
James Samuel ShannonDirector2025-06-1725,000$0.69
$17.23kBuy
Rene RussoPRESIDENT AND CEO2025-06-1636,289$0.68
$24.68kBuy
James Samuel ShannonDirector2025-06-1645,000$0.69
$30.87kBuy
Kevin M. BrennanSVP FINANCE AND ACCOUNTING2025-01-021,803$0.98
$1.77kSell
Christopher James FrankenfieldChief Financial Officer2025-01-026,954$0.98
$6.84kSell
Gilead Sciences Inc10% Owner2024-12-181,759,978$1.04
$1.83MBuy

1 of 1

XLO insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when XLO insiders and whales buy or sell their stock.

XLO Shareholders

What type of owners hold Xilio Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Gilead Sciences Inc17.57%9,105,451$6.39MInsider
Yekaterina Chudnovsky13.51%7,000,000$4.91MInsider
Sv7 Impact Medicine Fund LP6.23%3,227,264$2.27MInsider
Bain Capital Life Sciences Investors LLC5.41%2,805,413$1.97MInsider
Atlas Venture Fund XI LP5.31%2,754,109$1.93MInsider
James E. Flynn4.41%2,287,944$1.61MInsider
Takeda Pharmaceutical Co Ltd2.85%1,475,121$1.04MInsider
Rivervest Venture Fund IV LP2.78%1,441,444$1.01MInsider
Rock Springs Capital Management LP2.42%1,256,472$882.04kInsider
Vanguard Group Inc2.42%1,255,692$881.50kInstitution

1 of 3

XLO vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
XLO4.46%66.16%Net Buying
VRCA0.76%99.24%Net Selling
PPBT0.00%0.00%
VERU3.67%96.33%Net Buying
GBIO1.25%98.75%Net BuyingNet Selling
View Top Biotech Stocks

Xilio Therapeutics Stock Ownership FAQ

Who owns Xilio Therapeutics?

Xilio Therapeutics (NASDAQ: XLO) is owned by 4.46% institutional shareholders, 66.16% Xilio Therapeutics insiders, and 29.37% retail investors. Gilead Sciences Inc is the largest individual Xilio Therapeutics shareholder, owning 9.11M shares representing 17.34% of the company. Gilead Sciences Inc's Xilio Therapeutics shares are currently valued at $6.44M.

If you're new to stock investing, here's how to buy Xilio Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.